What We're Reading: Page 233
Industry reads hand-picked by our editors
May 24, 2019
-
CNN
Colorado is the first state to cap skyrocketing insulin co-pays
-
The Wall Street Journal
Trump Administration Preparing Executive Order on Health-Cost Disclosure
-
STAT
Powerful senators are taking surprisingly aggressive aim at PBMs
-
Bloomberg
Citi Says Biotech Tide May Turn as Large Deals Are Shunned
May 23, 2019
-
Bloomberg
AstraZeneca Offers a Perch to Cancer High Flier Who Stumbled
-
The Wall Street Journal
NYSE cuts fees to court biotech listings away from Nasdaq
-
The Atlantic
Why anti-vax doctors are ordering 23andMe tests
-
Axios
Former FDA head Scott Gottlieb rejoins venture capital firm New Enterprise Associates
May 22, 2019
-
CNBC
Novartis CEO says cannabis isn’t a focus despite Tilray partnership
-
FiercePharma
Lilly oncology suffers another blow as Verzenio slapped with safety warning in Japan
-
Bloomberg
India's biggest drugmaker plans to start developing its own medicines
-
TechCrunch
Famed founder Daphne Koller tells it straight: "With most drugs, we do not understand why they work"
May 20, 2019
May 17, 2019
-
Institutional Investor
This venture capital fund wants to get you pregnant
-
STAT
Thorny questions on apps matching cancer patients to clinical trials
-
Reuters
Five more U.S. states sue OxyContin maker Purdue Pharma over opioid epidemic
-
C&EN
With several long-acting HIV treatments in the works, the newest drugs emphasize convenience
May 16, 2019
-
The Wall Street Journal
Opioid makers draw scrutiny from hedge funds
-
Nikkei Asian Review
Pharma group Lupin joins India's push into biosimilar drugs
-
The Salt Lake Tribune
Two crucial antibiotics are the first products of Utah's new nonprofit drug company
-
Barron's
Bluebird Bio’s Pricing Plan Worries One Biotech Analyst
Previous
